Immunomedics, Inc. (IMMU): Price and Financial Metrics


Immunomedics, Inc. (IMMU)

Today's Latest Price: $85.25 USD

0.27 (-0.32%)

Updated Sep 29 4:00pm

Add IMMU to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 376 in Biotech

See all "A" rated Strong Buy stocks

IMMU Stock Summary

  • The ratio of debt to operating expenses for Immunomedics Inc is higher than it is for about only 6.28% of US stocks.
  • IMMU's price/sales ratio is 970.46; that's higher than the P/S ratio of 99.4% of US stocks.
  • Revenue growth over the past 12 months for Immunomedics Inc comes in at 6,804.75%, a number that bests 99.79% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to Immunomedics Inc, a group of peers worth examining would be ZLAB, LIFE, ITCI, CBMG, and CANF.
  • IMMU's SEC filings can be seen here. And to visit Immunomedics Inc's official web site, go to www.immunomedics.com.
IMMU Daily Price Range
IMMU 52-Week Price Range

IMMU Stock Price Chart Technical Analysis Charts


IMMU Price/Volume Stats

Current price $85.25 52-week high $86.91
Prev. close $85.52 52-week low $8.80
Day low $85.16 Volume 3,408,661
Day high $85.48 Avg. volume 3,932,596
50-day MA $52.41 Dividend yield N/A
200-day MA $31.42 Market Cap 19.71B

Immunomedics, Inc. (IMMU) Company Bio


Immunomedics, Inc. focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune, and other diseases. The company was founded in 1982 and is based in Morris Plains, New Jersey.


IMMU Latest News Stream


Event/Time News Detail
Loading, please wait...

IMMU Latest Social Stream


Loading social stream, please wait...

View Full IMMU Social Stream

Latest IMMU News From Around the Web

Below are the latest news stories about Immunomedics Inc that investors may wish to consider to help them evaluate IMMU as an investment opportunity.

Gilead Makes A Sizeable Bet On Immunomedics

Trodelvy. Source: Fierce Pharma Gilead (GILD) just unpacked part of its $21 billion war chest to acquire Immunomedics (IMMU) for $21 billion. "The agreement will provide Gilead with TrodelvyTM (sacituzumab govitecan-hziy), a first-in-class Trop-2 directed antibody-drug conjugate ((ADC)) that was granted accelerated approval by the U.S. Food and Drug Administration...

Shock Exchange on Seeking Alpha | September 26, 2020

IMPORTANT SHAREHOLDER ALERT: Halper Sadeh LLP Reminds Investors About Its Ongoing Investigations; Shareholders are Encouraged to Contact the Firm – CBMG, RST, IMMU, VAR

NEW YORK, NY / ACCESSWIRE / September 26, 2020 / Halper Sadeh LLP, a global investor rights law firm, is investigating:Cellular Biomedicine Group, Inc.

Yahoo | September 26, 2020

WeissLaw LLP Reminds MR, IMMU, and BMCH Shareholders About Its Ongoing Investigations

Montage Resources Corporation

Yahoo | September 26, 2020

SHAREHOLDER ALERT: WeissLaw LLP Reminds AKCA, IMMU, and MXIM Shareholders About Its Ongoing Investigations

If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact:

Yahoo | September 26, 2020

Top Healthcare Stocks for October 2020

These are the healthcare stocks with the best value, fastest growth, and most momentum for October 2020.

Yahoo | September 24, 2020

Read More 'IMMU' Stories Here

IMMU Price Returns

1-mo 103.51%
3-mo 130.97%
6-mo 700.47%
1-year 542.91%
3-year 509.80%
5-year 5,261.64%
YTD 302.88%
2019 48.28%
2018 -11.70%
2017 340.33%
2016 19.54%
2015 -36.04%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7779 seconds.